Cargando…

Folate-Receptor Positive Circulating Tumor Cell Is a Potential Diagnostic Marker of Prostate Cancer

Folate-receptor positive circulating tumor cells (FR+CTCs) shows an important role in the diagnosis and dynamic monitoring for many solid tumors; however, the application of FR+CTCs in prostate cancer remains unclear. We explored the potential application of FR+CTCs in this retrospective study. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Lian, Shenyi, Yang, Lujing, Feng, Qin, Wang, Ping, Wang, Yue, Li, Zhongwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531518/
https://www.ncbi.nlm.nih.gov/pubmed/34692484
http://dx.doi.org/10.3389/fonc.2021.708214
_version_ 1784586877203906560
author Lian, Shenyi
Yang, Lujing
Feng, Qin
Wang, Ping
Wang, Yue
Li, Zhongwu
author_facet Lian, Shenyi
Yang, Lujing
Feng, Qin
Wang, Ping
Wang, Yue
Li, Zhongwu
author_sort Lian, Shenyi
collection PubMed
description Folate-receptor positive circulating tumor cells (FR+CTCs) shows an important role in the diagnosis and dynamic monitoring for many solid tumors; however, the application of FR+CTCs in prostate cancer remains unclear. We explored the potential application of FR+CTCs in this retrospective study. The levels of FR+CTCs were detected in 30 prostate cancer patients and 7 bladder cancer patients in Peking University Cancer Hospital from August 2017 to August 2021. Clinical and pathology data were collected. One-way ANOVA was used to compare the difference in FR+CTCs levels in patients with prostate cancer, bladder cancer, and benign disease. The area under the receiver operating curve (AUROC) was used to compare the accuracy of FR+CTCs and tPSA in the diagnosis of prostate cancer. We found that levels of FR+CTCs were significantly higher in cancer patients (both prostate and bladder cancer) than in patients with benign urinary disease (p < 0.001). Besides, FR+CTCs level was consistently high in the prostate cancer patients with different tPSA levels (p < 0.001), and it was significantly higher in the patients with f/tPSA levels <0.16 than in those patients with f/tPSA levels >0.16 (12.20 ± 1.31 vs. 8.73 ± 0.92 FU/3 ml, p = 0.043). The diagnosis efficiency of FR+CTCs is better than the tPSA in prostate cancer patients with tPSA <10 ng/ml (0.871 vs. 0.857). In the prostate cancer patients with tPSA <10 ng/ml and f/tPSA <0.16, a combination of FR+CTCs and tPSA (AUROC, 0.934) further increased the diagnosis efficiency of each of these biomarkers alone (FR+CTCs, 0.912; tPSA, 0.857). Therefore, FR+CTCs could serve as an early diagnosis marker in the prostate cancer patients with uncertain tPSA levels.
format Online
Article
Text
id pubmed-8531518
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85315182021-10-23 Folate-Receptor Positive Circulating Tumor Cell Is a Potential Diagnostic Marker of Prostate Cancer Lian, Shenyi Yang, Lujing Feng, Qin Wang, Ping Wang, Yue Li, Zhongwu Front Oncol Oncology Folate-receptor positive circulating tumor cells (FR+CTCs) shows an important role in the diagnosis and dynamic monitoring for many solid tumors; however, the application of FR+CTCs in prostate cancer remains unclear. We explored the potential application of FR+CTCs in this retrospective study. The levels of FR+CTCs were detected in 30 prostate cancer patients and 7 bladder cancer patients in Peking University Cancer Hospital from August 2017 to August 2021. Clinical and pathology data were collected. One-way ANOVA was used to compare the difference in FR+CTCs levels in patients with prostate cancer, bladder cancer, and benign disease. The area under the receiver operating curve (AUROC) was used to compare the accuracy of FR+CTCs and tPSA in the diagnosis of prostate cancer. We found that levels of FR+CTCs were significantly higher in cancer patients (both prostate and bladder cancer) than in patients with benign urinary disease (p < 0.001). Besides, FR+CTCs level was consistently high in the prostate cancer patients with different tPSA levels (p < 0.001), and it was significantly higher in the patients with f/tPSA levels <0.16 than in those patients with f/tPSA levels >0.16 (12.20 ± 1.31 vs. 8.73 ± 0.92 FU/3 ml, p = 0.043). The diagnosis efficiency of FR+CTCs is better than the tPSA in prostate cancer patients with tPSA <10 ng/ml (0.871 vs. 0.857). In the prostate cancer patients with tPSA <10 ng/ml and f/tPSA <0.16, a combination of FR+CTCs and tPSA (AUROC, 0.934) further increased the diagnosis efficiency of each of these biomarkers alone (FR+CTCs, 0.912; tPSA, 0.857). Therefore, FR+CTCs could serve as an early diagnosis marker in the prostate cancer patients with uncertain tPSA levels. Frontiers Media S.A. 2021-10-08 /pmc/articles/PMC8531518/ /pubmed/34692484 http://dx.doi.org/10.3389/fonc.2021.708214 Text en Copyright © 2021 Lian, Yang, Feng, Wang, Wang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lian, Shenyi
Yang, Lujing
Feng, Qin
Wang, Ping
Wang, Yue
Li, Zhongwu
Folate-Receptor Positive Circulating Tumor Cell Is a Potential Diagnostic Marker of Prostate Cancer
title Folate-Receptor Positive Circulating Tumor Cell Is a Potential Diagnostic Marker of Prostate Cancer
title_full Folate-Receptor Positive Circulating Tumor Cell Is a Potential Diagnostic Marker of Prostate Cancer
title_fullStr Folate-Receptor Positive Circulating Tumor Cell Is a Potential Diagnostic Marker of Prostate Cancer
title_full_unstemmed Folate-Receptor Positive Circulating Tumor Cell Is a Potential Diagnostic Marker of Prostate Cancer
title_short Folate-Receptor Positive Circulating Tumor Cell Is a Potential Diagnostic Marker of Prostate Cancer
title_sort folate-receptor positive circulating tumor cell is a potential diagnostic marker of prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531518/
https://www.ncbi.nlm.nih.gov/pubmed/34692484
http://dx.doi.org/10.3389/fonc.2021.708214
work_keys_str_mv AT lianshenyi folatereceptorpositivecirculatingtumorcellisapotentialdiagnosticmarkerofprostatecancer
AT yanglujing folatereceptorpositivecirculatingtumorcellisapotentialdiagnosticmarkerofprostatecancer
AT fengqin folatereceptorpositivecirculatingtumorcellisapotentialdiagnosticmarkerofprostatecancer
AT wangping folatereceptorpositivecirculatingtumorcellisapotentialdiagnosticmarkerofprostatecancer
AT wangyue folatereceptorpositivecirculatingtumorcellisapotentialdiagnosticmarkerofprostatecancer
AT lizhongwu folatereceptorpositivecirculatingtumorcellisapotentialdiagnosticmarkerofprostatecancer